Hongmei Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hongmei Zhao has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Hong Sun
Department of Pharmacy, Eye & ENT Hospital, Fudan University, Shanghai, China
1 shared publication - Jia‐Li Tao
Department of Emergency The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University Huai'an China
1 shared publication - Man Luo
Department of Emergency, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huaian, China
1 shared publication Qing Zou
Department of Wound Treatment, The First Affiliated Hospital of Harbin Medical University, Harbin, P. R. China
1 shared publication- Qingsong Sun
Department of Emergency, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University
1 shared publication Rui-Chun Zhang
Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin, P. R. China
1 shared publication
Latest Publications
- Open Access
- 12 February 2020
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 36 (6) , 417-422
Overexpression of tripartite motif containing 26 inhibits non‐small cell lung cancer cell growth by suppressing PI3K/AKT signaling
It has been reported that tripartite motif containing 26 (TRIM26) is involved in the tumorigenesis of some cancers, but its function in non‐small cell lung cancer (NSCLC) is still unclear. In this study, we found that TRIM26 was markedly down‐regulated in both of NSCLC tumor tissues and cell lines. Additionally, high expression of TRIM26 in NSCLC patients predicted a positive index for patients' overall survival. What is more, overexpression of TRIM26 significantly suppressed NSCLC cell growth. Our further studies indicated that overexpression of TRIM26 inhibited the phosphorylation of PI3K p85 and AKT. And overexpressed TRIM26 regulated cell cycle‐related genes' expression, including downregulating CDK4, Cyclin A, Cyclin D1, Cyclin D3, and Cyclin E, and upregulating p27 expression. Finally, we found that TRIM26 up‐regulated PTEN expression by stabilizing PTEN protein in NSCLC cells. Collectively, our present study indicated that TRIM26 was decreased in NSCLC and overexpression of TRIM26 inhibited NSCLC cell growth by suppressing PI3K/AKT pathway, which suggested that TRIM26 could be as a potential target for the treatment of NSCLC in the future.
- 12 February 2020
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 36 (6) , 417-422
Open AccessOverexpression of tripartite motif containing 26 inhibits non‐small cell lung cancer cell growth by suppressing PI3K/AKT signaling
It has been reported that tripartite motif containing 26 (TRIM26) is involved in the tumorigenesis of some cancers, but its function in non‐small cell lung cancer (NSCLC) is still unclear. In this study, we found that TRIM26 was markedly down‐regulated in both of NSCLC tumor tissues and cell lines. Additionally, high expression of TRIM26 in NSCLC patients predicted a positive index for patients' overall survival. What is more, overexpression of TRIM26 significantly suppressed NSCLC cell growth. Our further studies indicated that overexpression of TRIM26 inhibited the phosphorylation of PI3K p85 and AKT. And overexpressed TRIM26 regulated cell cycle‐related genes' expression, including downregulating CDK4, Cyclin A, Cyclin D1, Cyclin D3, and Cyclin E, and upregulating p27 expression. Finally, we found that TRIM26 up‐regulated PTEN expression by stabilizing PTEN protein in NSCLC cells. Collectively, our present study indicated that TRIM26 was decreased in NSCLC and overexpression of TRIM26 inhibited NSCLC cell growth by suppressing PI3K/AKT pathway, which suggested that TRIM26 could be as a potential target for the treatment of NSCLC in the future.
- Open Access
- 7 July 2019
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 47 (9) , 4126-4133
Comparison of clinical outcomes and postoperative quality of life after surgical treatment of type II submucous myoma via laparoscopy or hysteroscopy
Objective: This study was performed to compare the clinical outcomes, advantages, and disadvantages of laparoscopic myomectomy (LM) and transcervical resection of myoma (TCRM) in the treatment of type II submucous myoma. Methods: In total, 136 patients with type II submucous myoma with a tumour diameter of 4 to 5 cm were randomly assigned to the hysteroscopy group or laparoscopy group. Results: The operative duration was shorter and the intraoperative bleeding volume was lower in the hysteroscopy than laparoscopy group. The success rate of the single-stage operation was obviously higher in the laparoscopy than hysteroscopy group. The duration of postoperative antibiotic use and the length of hospital stay were shorter in the hysteroscopy than laparoscopy group. The time to complete healing of the muscle layer was shorter in the hysteroscopy than laparoscopy group. The rate of intraoperative complications was lower in the hysteroscopy than laparoscopy group. Conclusion: Both hysteroscopic and laparoscopic surgery have beneficial effects in the treatment of type II submucous myoma. Hysteroscopic surgery has the advantages of a short operative duration, low intraoperative bleeding volume, fast postoperative recovery, and high quality of life. Laparoscopic surgery involves many intraoperative complications and slow recovery of ovarian function.
- 7 July 2019
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 47 (9) , 4126-4133
Open AccessComparison of clinical outcomes and postoperative quality of life after surgical treatment of type II submucous myoma via laparoscopy or hysteroscopy
Objective: This study was performed to compare the clinical outcomes, advantages, and disadvantages of laparoscopic myomectomy (LM) and transcervical resection of myoma (TCRM) in the treatment of type II submucous myoma. Methods: In total, 136 patients with type II submucous myoma with a tumour diameter of 4 to 5 cm were randomly assigned to the hysteroscopy group or laparoscopy group. Results: The operative duration was shorter and the intraoperative bleeding volume was lower in the hysteroscopy than laparoscopy group. The success rate of the single-stage operation was obviously higher in the laparoscopy than hysteroscopy group. The duration of postoperative antibiotic use and the length of hospital stay were shorter in the hysteroscopy than laparoscopy group. The time to complete healing of the muscle layer was shorter in the hysteroscopy than laparoscopy group. The rate of intraoperative complications was lower in the hysteroscopy than laparoscopy group. Conclusion: Both hysteroscopic and laparoscopic surgery have beneficial effects in the treatment of type II submucous myoma. Hysteroscopic surgery has the advantages of a short operative duration, low intraoperative bleeding volume, fast postoperative recovery, and high quality of life. Laparoscopic surgery involves many intraoperative complications and slow recovery of ovarian function.